A two-year evaluation of the ‘real life’ impact of COPD on patients in Germany: The DACCORD observational study

Respiratory Medicine

Volumn 124, Issue , 2017, Pages 57-64

  Kardos, Peter ^a   Vogelmeier, Claus ^b   Worth, Heinrich ^c   Buhl, Roland ^d   Lossi, Nadine S ^e   Mailänder, Claudia ^e   Criée, Carl Peter ^f  

^a Group Practice and Allergy   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c Praxis Drs Bily Kellermann   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e Novartis Pharma GmbH   (Germany)

^f Evangelical Hospital Goettingen Weende   (Germany)

Author keywords

CAT; COPD; Epidemiology; Exacerbations; Observational; Symptoms

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE IV INHIBITOR; THEOPHYLLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GERMANY; GROUPS BY AGE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT-REPORTED OUTCOME; PHARMACEUTICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; SAMPLE SIZE; SPIROMETRY; CLINICAL TRIAL; DRUG EFFECTS; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; SELF REPORT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; GERMANY; HUMANS; LUNG; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SELF REPORT; SPIROMETRY;

EID: 85013173363     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2017.02.007     Document Type: Article

References (16)

1. [1] Global Initiative for Chronic Obstructive Lung Disease, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2017 (Accessed 21 December 2016) www.goldcopd.org.
2. [2] Andersson, F., Borg, S., Jansson, S.A., Jonsson, A.C., Ericsson, A., Prütz, C., Rönmark, E., Lundbäck, B., The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir. Med. 96 (2002), 700–708.
3. [3] Dhamane, A., Moretz, C., Zhou, Y., Burslem, K., Saverno, K., Jain, G., Renda, A.M., Kaila, S., COPD exacerbation frequency and its association with health care resource utilization and costs. Int. J. Chron. Obstruct. Pulmon. Dis. 10 (2015), 2609–2618, 10.2147/COPD.S90148.
4. [4] Thomas, M., Radwan, A., Stonham, C., Marshall, S., COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care. COPD 11 (2014), 300–309, 10.3109/15412555.2013.841671.
5. [5] Punekar, Y.S., Shukla, A., Müllerova, H., COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int. J. Chron. Obstruct. Pulmon. Dis. 9 (2014), 65–73, 10.2147/COPD.S54417.
6. [6] Jansson, S.-A., Backman, H., Rönmark, E., Lundbäck, B., Lindberg, A., Hospitalization due to co-morbid conditions is the main cost driver among subjects with COPD-A report from the population-based OLIN COPD study. COPD 12 (2015), 381–389, 10.3109/15412555.2014.974089.
7. [7] Rabe, K.F., Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategies. Proc. Am. Thorac. Soc. 3 (2006), 270–275, 10.1513/pats.200601-002SF.
8. [8] Calverley, P.M.A., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W., Yates, J.C., Vestbo, J., on behalf of the TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356 (2007), 775–789, 10.1056/NEJMoa063070.
9. [9] Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., Decramer, M., Investigators, U.S., A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 359 (2008), 1543–1554, 10.1056/NEJMoa0805800.
10. [10] Vaes, A.W., Garcia-Aymerich, J., Marott, J.L., Benet, M., Groenen, M.T.J., Schnohr, P., Franssen, F.M.E., Vestbo, J., Wouters, E.F.M., Lange, P., Spruit, M.A., Changes in physical activity and all-cause mortality in COPD. Eur. Respir. J. 44 (2014), 1199–1209, 10.1183/09031936.00023214.
11. [11] Tantucci, C., Modina, D., Lung function decline in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 7 (2012), 95–99, 10.2147/COPD.S27480.
12. [12] Kardos, P., Vogelmeier, C., Buhl, R., Criée, C.-P., Worth, H., The prospective non-interventional DACCORD Study in the National COPD Registry in Germany: design and methods. BMC Pulm. Med., 15, 2015, 2, 10.1186/1471-2466-15-2.
13. [13] Worth, H., Buhl, R., Criée, C.-P., Kardos, P., Mailänder, C., Vogelmeier, C., The “real-life” COPD patient in Germany: the DACCORD study. Respir. Med. 111 (2016), 64–71, 10.1016/j.rmed.2015.12.010.
14. [14] Buhl, R., Criée, C.-P., Kardos, P., Vogelmeier, C., Lossi, N., Mailaender, C., Worth, H., A year in the life of German patients with COPD: the DACCORD observational study. Int. J. Chron. Obstruct. Pulmon. Dis. Vol. 11 (2016), 1639–1646, 10.2147/COPD.S112110.
15. [15] Hurst, J.R., Vestbo, J., Anzueto, A., Locantore, N., Müllerova, H., Tal-Singer, R., Miller, B., Lomas, D.A., Agusti, A., Macnee, W., Calverley, P., Rennard, S., Wouters, E.F.M., Wedzicha, J.A., For the evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigators, susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 363 (2010), 1128–1138, 10.1056/NEJMoa0909883.
16. [16] Ställberg, B., Janson, C., Johansson, G., Larsson, K., Stratelis, G., Telg, G., Lisspers, K.H., Management, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS). Prim. Care Respir. J. 23 (2014), 38–45, 10.4104/pcrj.2013.00106.